Trial Profile

First in human study of AK006

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 31 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AK 006 (Primary)
Indications Inflammation
Focus Adverse reactions; First in man
Sponsors Allakos

Most Recent Events

31 Jan 2025 Status changed from planning to withdrawn prior to enrolment.
09 Aug 2023 According to Allakos media release, AK006 Investigational New Drug (IND) application was accepted by the U.S. Food and Drug Administration
08 Mar 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com